United States
Securities and Exchange Commission
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15[d] of the Securities Exchange Act of 1934
January 17, 2020
Date of Report
Q2EARTH, INC.
(Exact name of Registrant as specified in its Charter)
Delaware | 000-55148 | 20-1602779 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
420 Royal Palm Way, #100
Palm beach, FL 33480
(Address of Principal Executive Offices)
(561) 693-1423
(Registrant’s Telephone Number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14-a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchanged on Which Registered | ||
Common Stock | QPWR |
OTCQB |
Item 5.02 | Election of Director; Departure of Certain Officers; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
On January 16, 2020, the Board of Directors of Q2Earth, Inc. (“Q2Earth” or the “Company”) appointed Douglas R. Baum as a director of Q2Earth, effective immediately. Mr. Baum currently serves as a consultant to several drug development companies. From 2011 to January 2017 he served as President and CEO at Xeris Pharmaceuticals overseeing production of approvals through the FDA and capital raising.
Other than his appointment to the Q2Earth board during the past 5 years, Mr. Baum has not served on the board of directors of any company that was required to file reports pursuant to the Securities Exchange Act of 1934, as amended, or was a registered investment company under the Investment Company Act of 1940, as amended. Mr. Baum was granted a 5-year option to purchase 200,000 shares of the Company’s commons stock exercisable at $0.02 per share. The options vest one-half in 12 months and the balance in 24 months.
The Company issued a Press Release announcing the appointment of Mr. Baum, copy of which is attached as Exhibit 99.1 and is incorporated by reference
Item 9.01 | Financial Statements Pro Forma Financial Information and Exhibits. |
(d) | Exhibits | |
Exhibit No. | Description | |
99.1 | Press Release issued by Q2Earth on January 16, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
Q2EARTH INC. | ||
Date: January 17, 2020 | By: | /s/ Kevin Bolin |
Kevin Bolin | ||
Chief Executive Officer |